Researchers have developed a new nanoparticle-based treatment that reduces blood sugar in diabetic mice by turning off a liver protein called Sam68, according to a 2026 study published in the Journal of Nanobiotechnology. The galactose-decorated nanoparticles successfully delivered genetic instructions to liver cells, suppressing excessive glucose production and improving insulin sensitivity in both genetically engineered and diet-induced diabetic mice. While these results are promising, the treatment remains in early laboratory and animal testing stages and has not been tested in humans.
Scientists have developed a new treatment using tiny particles called lipid nanoparticles (LNPs) to deliver medicine directly to the liver. According to Gram Research analysis, this approach targets a protein called Sam68 that appears to be overactive in people with type 2 diabetes. In laboratory and animal studies, turning off this protein reduced blood sugar levels and improved how the body responds to insulin. The treatment worked by stopping the liver from making too much glucose, which is a major problem in diabetes. While these results are exciting, the treatment is still in early testing stages and hasn’t been tested in humans yet.
Key Statistics
A 2026 research article in the Journal of Nanobiotechnology found that galactose-decorated lipid nanoparticles successfully silenced the Sam68 protein in liver cells and improved blood sugar control in diabetic mice.
According to the 2026 study, the nanoparticle treatment improved insulin sensitivity and reduced hepatic glucose production in both genetically engineered and diet-induced diabetic mouse models.
Gram Research analysis of the 2026 research shows the galactose-decorated nanoparticle system demonstrated a favorable safety profile in laboratory and animal studies without serious harmful effects observed.
The Quick Take
- What they studied: Whether a new nanoparticle-based treatment could reduce blood sugar levels in type 2 diabetes by turning off a specific liver protein
- Who participated: Laboratory cell cultures and two different types of diabetic mice (genetically engineered and those fed a high-fat diet)
- Key finding: The galactose-decorated nanoparticle treatment successfully silenced the Sam68 protein in liver cells, reduced glucose production, and improved blood sugar control and insulin sensitivity in diabetic mice
- What it means for you: This represents an early-stage discovery that could eventually lead to a new type of diabetes treatment, but it’s not ready for human use yet. More testing is needed to confirm safety and effectiveness in people
The Research Details
Researchers created special tiny particles called lipid nanoparticles (LNPs) and decorated them with galactose, a natural sugar. These particles were designed to carry genetic instructions (siRNA) that could turn off the Sam68 gene specifically in liver cells. The team tested this approach in two ways: first in liver cells grown in dishes, and then in living mice with diabetes. They used two different mouse models—one genetically engineered to have diabetes and another that developed diabetes from eating a high-fat diet, similar to how some humans develop type 2 diabetes.
The researchers chose this approach because the liver is the main organ responsible for making glucose when blood sugar is low. In people with type 2 diabetes, the liver makes too much glucose, which keeps blood sugar dangerously high. Previous research showed that a protein called Sam68 is overactive in diabetic livers. By using nanoparticles decorated with galactose (which liver cells naturally recognize and absorb), the researchers could deliver medicine directly to liver cells without affecting other parts of the body.
After treatment, the team measured multiple outcomes including blood sugar levels, how well insulin worked, and how much glucose the liver was producing. They also checked for any harmful side effects in the treated animals.
This research matters because current type 2 diabetes treatments don’t always work well enough, and many people need multiple medications. A treatment that targets the root cause—excessive glucose production in the liver—could be more effective. The nanoparticle delivery system is also important because it allows medicine to reach specific organs without affecting the whole body, potentially reducing side effects. This represents a new category of treatment called RNA interference therapy, which works differently than traditional diabetes drugs.
This is early-stage laboratory and animal research, which means results are promising but not yet proven in humans. The study was published in a peer-reviewed scientific journal, suggesting it met quality standards for publication. However, animal studies don’t always translate to human results. The researchers tested their approach in two different mouse models, which strengthens confidence in the findings. The study included both laboratory experiments and living animal models, providing multiple lines of evidence. Important limitations include the lack of human testing and unknown long-term effects in living organisms.
What the Results Show
The galactose-decorated nanoparticles successfully delivered the genetic instructions to liver cells and turned off the Sam68 protein in both laboratory and animal studies. In diabetic mice, this treatment improved blood sugar control, meaning glucose levels stayed closer to normal. The treatment also improved insulin sensitivity, which means the mice’s bodies responded better to insulin and could use glucose more effectively.
The researchers found that the nanoparticle treatment reduced the amount of glucose the liver was producing. This is important because excessive liver glucose production is a major reason why people with type 2 diabetes have high blood sugar. By suppressing this process, the treatment addressed a fundamental problem in diabetes.
The treatment showed a favorable safety profile in the studies, meaning no serious harmful effects were observed in the tested animals. The nanoparticles were able to reach liver cells specifically without accumulating in other organs in dangerous amounts. The researchers also confirmed that the treatment worked in both genetically engineered diabetic mice and mice that developed diabetes from diet, suggesting the approach might work across different types of diabetes.
The research showed that the nanoparticle system successfully suppressed the entire gluconeogenic program in the liver—meaning it didn’t just turn off one protein, but affected the whole system that makes glucose. This suggests the treatment works through a comprehensive mechanism rather than just a single effect. The treatment improved insulin responsiveness, which means the body’s cells became better at responding to insulin signals, a key problem in type 2 diabetes.
This research builds on earlier work showing that Sam68 is overactive in diabetic livers. Previous studies had shown that removing Sam68 in mice improved diabetes symptoms, but those studies used genetic engineering that isn’t practical for treating humans. This new research translates that finding into a potentially practical treatment using nanoparticles. The nanoparticle delivery approach is novel and represents an advance in how researchers can target specific organs with genetic medicines.
The most important limitation is that this research has only been tested in mice, not in humans. Animal studies often don’t produce the same results in people. The study didn’t specify the exact sample sizes for all experiments, making it harder to assess statistical power. Long-term effects are unknown—the study shows short-term benefits but doesn’t address whether the treatment remains effective over months or years. The research doesn’t compare this treatment to existing diabetes medications, so it’s unclear how it would perform against current standard treatments. The nanoparticle formulation is new and would need extensive safety testing before any human trials could begin. The study was conducted in controlled laboratory and animal settings, which don’t capture the complexity of human disease and individual variation.
The Bottom Line
This treatment is not ready for human use and should not be considered a current option for diabetes management. People with type 2 diabetes should continue using proven treatments prescribed by their doctors. For researchers and pharmaceutical companies, this work suggests a promising direction for future drug development. The evidence is strong enough to warrant further research and development, but confidence in human effectiveness remains low until clinical trials are conducted.
This research is most relevant to people with type 2 diabetes who are interested in emerging treatments, though they should not expect this to be available soon. Researchers in diabetes, genetic medicine, and nanotechnology should pay attention to this work. Pharmaceutical companies developing new diabetes treatments may be interested in this approach. People with type 2 diabetes who struggle with current medications might eventually benefit if this treatment successfully moves through human testing. This research is less relevant to people with type 1 diabetes, which has a different cause.
If this treatment follows typical drug development timelines, it would take at least 5-10 years before human testing could begin, and potentially 10-15 years total before it might become available as a treatment. First, researchers need to conduct more animal studies and safety testing. Then regulatory agencies would need to approve human trials. Clinical trials in humans typically take several years. Even if everything goes smoothly, this treatment is likely 10+ years away from potential availability.
Frequently Asked Questions
Is there a new nanoparticle treatment for type 2 diabetes available now?
No, this nanoparticle treatment is still in early research stages and has only been tested in mice. It has not been tested in humans and is likely 10+ years away from potential availability, pending further research and regulatory approval.
How do these nanoparticles target the liver specifically?
The nanoparticles are decorated with galactose, a natural sugar that liver cells recognize and absorb. This targeting allows the medicine to reach liver cells specifically without affecting other parts of the body, potentially reducing side effects.
What is Sam68 and why is it important in diabetes?
Sam68 is a protein that is overactive in the livers of people with type 2 diabetes. It contributes to excessive glucose production by the liver, which keeps blood sugar dangerously high. Turning off this protein reduces glucose production.
Could this treatment replace my current diabetes medications?
Not yet. This treatment is experimental and only tested in animals. People with type 2 diabetes should continue using proven medications prescribed by their doctors. This research may eventually lead to new treatment options, but that’s years away.
Why do researchers use mice to test diabetes treatments?
Mice develop diabetes similarly to humans and have comparable liver biology. Testing in mice helps researchers understand if a treatment works before attempting human trials. However, results in mice don’t always translate to humans, requiring further testing.
Want to Apply This Research?
- Users interested in diabetes research developments could track emerging treatment news by setting reminders to check clinical trial databases quarterly. They could also monitor their own blood sugar patterns using their app to establish a baseline for comparison if they ever participate in future clinical trials.
- While this specific treatment isn’t available yet, users can use the app to optimize current diabetes management by tracking blood sugar patterns, medication timing, and lifestyle factors that affect glucose production. This data will be valuable if they want to participate in future clinical trials for new treatments.
- Set up a quarterly reminder to check ClinicalTrials.gov for any human studies testing this nanoparticle approach. Track current blood sugar control metrics in the app to establish a personal baseline. Document any new diabetes medications or treatments you try, creating a record that could help researchers understand your response to future therapies.
This article describes early-stage research that has not been tested in humans. The nanoparticle treatment discussed is experimental and not available for human use. People with type 2 diabetes should not consider this a current treatment option and should continue following their doctor’s recommendations for diabetes management. This research is presented for informational purposes only and should not be interpreted as medical advice. Always consult with a healthcare provider before making any changes to diabetes treatment or management. Future human testing may reveal safety or effectiveness issues not apparent in animal studies.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.